ClinicalTrials.gg
RecruitingNCT04755569Updated Aug 2, 2023

Optimizer System With ODOCOR II CCM™ Leads

An observational study in Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead, sponsored by Impulse Dynamics. Recruiting at 40 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-02.

Sponsored by Impulse Dynamics · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the ODOCOR II CCM lead study is to evaluate the safety and useability of the ODOCOR II intra-cardiac lead specifically intended to deliver CCM as an accessory lead to the Optimizer IPG.

Read the detailed description

Design A prospective, multi-center, single arm open label study, 12-month study of 400 ODOCOR II CCM™ leads in 200 subjects .

Method Subjects shall be enrolled that have been diagnosed with NYHA Class III-IV heart failure and left ventricular ejection fraction (25-45% inclusive). Eligible subjects will receive the Optimizer IPG device implant with 2 ODOCOR II CCM leads. Subjects will return for follow-up visits at 2-weeks, 6 months and 12 months following the device implant.

Endpoints Primary Safety endpoint

The primary safety endpoint is the incidence of lead-related complication free rate at 12 months post-index implantation procedure compared to the incidence previously described in the literature for pacing therapy leads.

Secondary Safety endpoint

The secondary safety endpoint is an assessment of the lead-related "observations" occurring during the 12-month study.

Primary Efficacy endpoint The total amount of CCM delivered to the cardiac tissue of the right ventricle (measured by CCM percentage) will be measured over a period of 12 months.

Secondary Efficacy endpoint Change in QOL, as measured by the Minnesota Living with Heart Failure Questionnaire (MLWHFQ), from baseline to 12 months following index implantation procedure.

Additional Endpoints Handling characteristics of the lead will be evaluated by the implanting physician. Ease of insertion, lead visibility on x-ray, and the ability to visualize the helix deployment will be assessed via a questionnaire administered at the completion of an implant procedure.

Patients, sites Four hundred (400) ODOCOR II CCM leads will be implanted in 200 eligible subjects from up to 40 sites in Europe.

Duration The total investigation is expected to last approximately 3 years , including enrollment and follow-up periods.

02

Conditions studied

  • Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead
03

In context

Lead sponsor

Impulse Dynamics is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The total investigation is expected to last approximately 3 years , including enrollment and follow-up periods.

Four hundred (400) ODOCOR II CCM leads will be implanted in 200 eligible subjects from up to 40 sites in Europe

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient signed and dated form
  2. Male or non-pregnant female, aged 18 or older
  3. of 25-45% (inclusive)
  4. Diagnosed with Class III or IV heart failure
  5. Stated willingness to comply with all study procedures and availability for the duration of the study
  6. Medically stable and with no significant mental illness in the judgement of the principal investigator

Exclusion criteria

Exclusion Criteria:

  1. Infiltrative or inflammatory cardiomyopathy (e.g. amyloid, hemochromatosis, myocarditis, hypertrophic cardiomyopathy, Fabry's disease, cardiac tumor)
  2. Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair or clip within 3 months of the baseline testing visit.
  3. IV inotropes, hemofiltration, or any form of positive inotropic support within 30 days before the baseline testing visit, including continuous IV inotrope therapy
  4. Myocardial infarction within 3 months of the baseline testing visit.
  5. Undergone a CABG procedure within 3 months90 days or a PTCA procedure within 30 days of the baseline testing visit.
  6. Undergone a cardiac ablation procedure within 90 days prior to consent.
  7. Prior heart transplant or ventricular assist device
  8. Mechanical tricuspid valve
  9. Receiving cardiac resynchronization therapy (CRT) or indicated for Class I CRT implantation according to the ACCF/AHA/HRS guidelines for device-based therapy
  10. Currently on dialysis
  11. Currently undergoing active chemotherapeutic and/or radiation treatment for cancer
  12. Participating in another cardiac device study at the same time
  13. Patient is in a vulnerable population (such as significant mental disability, prisoner) that in the judgement of the PI impedes ability to provide informed content.
  14. Expected lifespan of less than 12 months from time the baseline testing visit.
  15. Resting heart rate >110 bpm at the time of the baseline testing visit
  16. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  17. Subjects currently admitted to the hospital with a primary diagnosis of heart failure

    -

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • DeviceODOCOR II CCM LEADS

    ODOCOR II CCM LEADS Implantation

06

What researchers measure

Primary outcomes

  1. Primary Safety endpoint

    The primary safety endpoint is the incidence of lead-related complication free rate at 12 months post-index implantation procedure compared to the incidence previously described in the literature for pacing therapy leads.

    Time frame: 12 months

  2. Primary Efficacy endpoint

    The total amount of CCM delivered to the cardiac tissue of the right ventricle (measured by CCM percentage) will be measured over a period of 12 months.

    Time frame: 12 month

Secondary outcomes

  1. Secondary Safety endpoint

    The secondary safety endpoint is an assessment of the lead-related "observations" occurring during the 12-month study.

    Time frame: 12 month

  2. Secondary Efficacy endpoint

    Change in QOL, as measured by the Minnesota Living with Heart Failure Questionnaire (MLWHFQ), from baseline to 12 months following index implantation procedure.

    Time frame: 12 month

Other outcomes

  1. Additional Endpoints

    Handling characteristics of the lead will be evaluated by the implanting physician. Ease of insertion, lead visibility on x-ray, and the ability to visualize the helix deployment will be assessed via a questionnaire administered at the completion of an implant procedure.

    Time frame: at implant

07

Study locations

33 of 40 sites recruiting
  • Klinik am Plattenwald
    Heilbronn, Baden Wuerttemberg 74177, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • St. Anna Krankenhaus
    Sulzbach-Rosenberg, Bavaria 92237, Germany
    Recruiting
    • Flamur Kryezi, Dr. · Contactf.kryezi@kh-as.de · +49 170 1039794
    • Flamur Kryezi, Dr. · Principal investigator
  • St. Josefs-Hospital Wiesbaden GmbH
    Wiesbaden, Hessen 65189, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Elbe Klinikum Stade
    Stade, Lower Saxony 21682, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Krankenhaus Marie-Hilf Stadtlohn
    Stadtlohn, North Rhine Westphalia 48703, Germany
    Recruiting
  • Augusta-Kranken-Anstalt Bochum-Mitte
    Bochum, North Rhine-Westphalia 44791, Germany
    Recruiting
  • Klinikum Magdeburg
    Magdeburg, Saxony-Anhalt 39120, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Herzzentrum Dresden
    Dresden, Saxony 01307, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • DRK Kliniken Berlin Koepenick
    Berlin, 12559, Germany
    Recruiting
  • Charité Berlin Campus Virchow
    Berlin, 13353, Germany
    Recruiting
  • Evangelisches Klinikum Bethel
    Bielefeld, 33617, Germany
    Recruiting
    • Carsten W. Israel · Contactcarsten.israel@evkb.de · +49 52177277525
    • Christina Schaefer · Contact+49 521 772 77640
    • Carsten W. Israel · Principal investigator
    • Tobias Feldmann · Sub investigator
  • Regiomed Kliniken-Coburg
    Coburg, Germany
    Recruiting
  • SRH Krankenhaus Waltershausen-Friedrichroda
    Friedrichroda, 99894, Germany
    Recruiting
  • Marienhospital
    Gelsenkirchen, 45886, Germany
    Recruiting
  • Asklepios Klinik St. Georg
    Hamburg, 20099, Germany
    Recruiting
  • Schoen Klinik Hamburg Eilbek
    Hamburg, 22081, Germany
    Recruiting
  • Evangelisches Krankenhaus Herne
    Herne, 44623, Germany
    Recruiting
  • St. Marien-Hospital Klinikum Luenen
    Lünen, D-44534, Germany
    Not yet recruiting
  • Universitaetsklinikum UMM
    Mannheim, Germany
    Recruiting
    • Juergen Kuschyk, Prof. Dr. · Contactjuergen.kuschyk@umm.de · +49 1713453211
    • Brigitte Kircher · Contactbrigitte.kircher@umm.de · +49 6213831993
    • Juergen Kuschyk · Principal investigator
    • Boris Rudic · Sub investigator
  • Niels-Stensen-Kliniken Marienhospital Osnabrück GmbH
    Osnabrück, 49074, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Dei Colli-Monaldi
    Naples, Campania 80131, Italy
    Recruiting
  • Ospedale "Sacra Famiglia" - Fatebenefratelli dell'
    Erba, Lombardo Veneta 22036, Italy
    Recruiting
  • Ente Ecclesiastico Ospedale Generale Regionale "F.Miulli" Cardiologia e U.T.I.C.
    Acquaviva Delle Fonti, Italy
    Recruiting
    • Vincenzo Caccavo, Dr. · Contactv.caccavo73@gmail.com
    • Vincenzo Caccavo, Dr. · Principal investigator
    • Nicola Vitulano, Dr. · Sub investigator
  • Ospedale C. e G. "Mazzoni"
    Ascoli Piceno, 63100, Italy
    Recruiting
  • Ospedale San Paolo, UOC Cardiologia ed UTIC
    Bari, 70123, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Consorziale - Policlinico di Bari U.O.C Cardiologia Ospedaliera
    Bari, Italy
    Recruiting
  • IRCCS Policlinico Sant'Orsola-Malpighi
    Bologna, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria di Cagliari
    Cagliari, Italy
    Recruiting
  • Azienda Sanitaria Provinciale di Cosenza "Ospedale di Castrovillari
    Castrovillari, Italy
    Recruiting
    • Silvana De Bonis, Dr. · Contactsilvanadebonis68@gmail.com
    • Silvana De Bonis, Dr. · Principal investigator
    • Antonio Mazziotti, Dr. · Sub investigator
  • ASL TO 4 - Presidio Ospedaliero Riunito sede di Cirie
    Ciriè, Italy
    Recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Maggiore della Carita
    Novara, 28100, Italy
    Recruiting
    • Giuseppe Patti · Contactgiuseppe.patti@maggioreosp.novara.it
    • Giuseppe Patti · Principal investigator
    • Gabriele Dell'Era · Sub investigator
    • Camilla Marconetto · Sub investigator
  • Gruppo Synergo - Casa Di Cura Pierangeli
    Pescara, 65124, Italy
    Recruiting
  • Presidio Ospedaliero Sant'Andrea
    Vercelli, 13100, Italy
    Recruiting
    • Francesco Rametta, Dr · Contactframetta@alice.it · +39 3475367363
    • Francesco Rametta · Principal investigator
  • Ospedale San Bortolo di Vicenza - Azienda UlSS 8 Berica
    Vicenza, 36100, Italy
    Recruiting
  • Complejo Hospitario Torrecardenas
    Almería, 04009, Spain
    Recruiting
  • Hospital Virgen de las Nieves
    Granada, 18014, Spain
    Recruiting
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Javier de Juan Baguda, Dr. · Contact
    • Ana Benito · Contactana.benito12@hotmail.com
    • Javier de Juan Baguda, Dr. · Principal investigator
  • Hospital Puerta de Hierro
    Madrid, 28222, Spain
    Recruiting
  • Hospital Clinico U. de Santiago
    Santiago De Compostela, 15706, Spain
    Recruiting
    • Javier Garcia Seara, Dr. · Contact
    • Jose Seijas · Contactjose.seijas.amigo@gmail.com
    • Javier Garcia Seara, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Dec 2024, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2021
First posted
Feb 16, 2021
StartActual
Mar 1, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Aug 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04755569
Lead sponsor
Impulse Dynamics
Responsible party
Sponsor
First posted
Feb 16, 2021
Start date
Mar 1, 2021
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 2, 2023

Study contacts

Angela Stagg
Contact
astagg@impulsedynamics.com
+01 845 558 9391
Stefano DeVivo, MD
principal investigator · Monaldi Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion